title: Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance.
abstract: The frequency of loss of heterozygosity (LOH) around MMAC/PTEN and DMBT1 loci and survival analyses based on the LOH status were assessed in 110 patients with different histological groups of gliomas. Twenty-six of the patients had anaplastic oligodendrogliomas, 31 had anaplastic astrocytomas, and 53 had glioblastomas multiforme (GM). At the DMBT1 locus, LOH was observed very frequently in all three histological groups, with no significant difference in the frequency of LOH among the three histological groups. At the MMAC/PTEN locus, patients with GM exhibited a significantly increased frequency of LOH (72%) compared with patients with anaplastic astrocytomas (29%) or anaplastic oligodendrogliomas (31%) (P < 0.0001). Kaplan-Meier survival plots showed that patients with LOH at the MMAC/PTEN locus had a significantly worse prognosis than did patients without LOH at the MMAC/PTEN locus [hazard ratio (LOH versus non-LOH), 2.65; 95% confidence interval (CI), 1.69-4.46; P < 0.0001]. Cox proportional hazards regression analysis, adjusted for age at surgery and histological grades (GM and non-GM), showed that LOH at the MMAC/PTEN locus was a significant predictor of shorter survival [hazard ratio (LOH versus non-LOH), 2.01; 95% CI, 1.1-3.5; P = 0.018). Our analysis failed to indicate a similar association between the frequency of LOH at the DMBT1 locus and patient survival [hazard ratio (LOH versus non-LOH), 2; 95% CI, 0.37-3.13; P = 0.2]. These results suggest that the DMBT1 gene may be involved early in the oncogenesis of gliomas, whereas alterations in the MMAC/PTEN gene may be a late event in the oncogenesis related to progression of gliomas and provide a significant prognostic marker for patient survival.
authors.affiliation: Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
authors.forename: H
authors.initials: H
authors.lastname: Lin
authors.forename: M L
authors.initials: ML
authors.lastname: Bondy
authors.forename: L A
authors.initials: LA
authors.lastname: Langford
authors.forename: K R
authors.initials: KR
authors.lastname: Hess
authors.forename: G L
authors.initials: GL
authors.lastname: Delclos
authors.forename: X
authors.initials: X
authors.lastname: Wu
authors.forename: W
authors.initials: W
authors.lastname: Chan
authors.forename: M A
authors.initials: MA
authors.lastname: Pershouse
authors.forename: W K
authors.initials: WK
authors.lastname: Yung
authors.forename: P A
authors.initials: PA
authors.lastname: Steck
mesh_terms: D000373:Agglutinins; D002135:Calcium-Binding Proteins; D002874:Chromosome Mapping; D004268:DNA-Binding Proteins; D016147:Genes, Tumor Suppressor; D005910:Glioma / Q000235:genetics* / Q000401:mortality; D006801:Humans; D019656:Loss of Heterozygosity; D051059:PTEN Phosphohydrolase; D010744:Phosphoric Monoester Hydrolases / Q000235:genetics*; D011379:Prognosis; D011956:Receptors, Cell Surface / Q000235:genetics*; D015996:Survival Rate; D025521:Tumor Suppressor Proteins
chemical_list: D000373:Agglutinins; D002135:Calcium-Binding Proteins; C108174:DMBT1 protein, human; D004268:DNA-Binding Proteins; D011956:Receptors, Cell Surface; D025521:Tumor Suppressor Proteins; D010744:Phosphoric Monoester Hydrolases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human